CD8A and primary cutaneous T-cell non-Hodgkin lymphoma: Therefore, the potential for development of an anti-malignant T cell immune response exists in CTCL patients and immunotherapeutic approaches designed to expand anti-tumor CD8 T cells could be effective in this disease.